IDYA IDEAYA Biosciences Inc

Price (delayed)

$31.45

Market cap

$2.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.99

Enterprise value

$1.88B

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates ...

Highlights
The quick ratio has soared by 61% YoY
The company's debt fell by 47% YoY and by 18% QoQ
The net income has plunged by 96% YoY and by 39% from the previous quarter
The revenue has dropped by 53% year-on-year and by 48% since the previous quarter

Key stats

What are the main financial stats of IDYA
Market
Shares outstanding
64.46M
Market cap
$2.03B
Enterprise value
$1.88B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.56
Price to sales (P/S)
80.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
79.92
Earnings
Revenue
$23.48M
EBIT
-$103.21M
EBITDA
-$100.72M
Free cash flow
-$116.38M
Per share
EPS
-$1.99
Free cash flow per share
-$1.94
Book value per share
$8.83
Revenue per share
$0.39
TBVPS
$8.88
Balance sheet
Total assets
$532.94M
Total liabilities
$24.89M
Debt
$2.1M
Equity
$508.05M
Working capital
$457.29M
Liquidity
Debt to equity
0
Current ratio
19.37
Quick ratio
19.13
Net debt/EBITDA
1.49
Margins
EBITDA margin
-428.9%
Gross margin
100%
Net margin
-439.5%
Operating margin
-506.5%
Efficiency
Return on assets
-22.8%
Return on equity
-24.4%
Return on invested capital
-31.3%
Return on capital employed
-20.3%
Return on sales
-439.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IDYA stock price

How has the IDEAYA Biosciences stock price performed over time
Intraday
0.9%
1 week
-0.47%
1 month
22.09%
1 year
75.89%
YTD
73.09%
QTD
16.57%

Financial performance

How have IDEAYA Biosciences's revenue and profit performed over time
Revenue
$23.48M
Gross profit
$23.48M
Operating income
-$118.96M
Net income
-$103.21M
Gross margin
100%
Net margin
-439.5%
IDEAYA Biosciences's operating margin has plunged by 170% from the previous quarter
The company's net margin has shrunk by 167% QoQ
IDYA's operating income has dropped by 119% year-on-year and by 40% since the previous quarter
The net income has plunged by 96% YoY and by 39% from the previous quarter

Growth

What is IDEAYA Biosciences's growth rate over time

Valuation

What is IDEAYA Biosciences stock price valuation
P/E
N/A
P/B
3.56
P/S
80.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
79.92
The EPS has declined by 44% year-on-year and by 34% since the previous quarter
The stock's P/B is 62% above its 5-year quarterly average of 2.2 and 37% above its last 4 quarters average of 2.6
IDEAYA Biosciences's equity has increased by 38% YoY
The stock's price to sales (P/S) is 153% more than its last 4 quarters average of 31.8
The revenue has dropped by 53% year-on-year and by 48% since the previous quarter

Efficiency

How efficient is IDEAYA Biosciences business performance
The return on sales has dropped by 167% since the previous quarter
The ROA has plunged by 62% YoY and by 30% from the previous quarter
IDYA's ROIC has plunged by 51% YoY and by 31% from the previous quarter
The company's return on equity fell by 42% YoY and by 28% QoQ

Dividends

What is IDYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IDYA.

Financial health

How did IDEAYA Biosciences financials performed over time
The quick ratio has soared by 61% YoY
IDYA's current ratio has soared by 61% YoY but it is down by 2.2% QoQ
The company's debt is 100% lower than its equity
IDEAYA Biosciences's debt to equity has shrunk by 100% QoQ and by 100% YoY
The company's debt fell by 47% YoY and by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.